These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24346227)

  • 1. Pharmacological and clinical differences among transmucosal fentanyl formulations for the treatment of breakthrough cancer pain: a review article.
    Corli O; Roberto A
    Minerva Anestesiol; 2014 Oct; 80(10):1123-34. PubMed ID: 24346227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
    Am J Hosp Palliat Care; 2005; 22(3):228-32. PubMed ID: 15909786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fentanyl sublingual tablets. Breakthrough pain: new formulation, no therapeutic advantage.
    Prescrire Int; 2010 Feb; 19(105):16. PubMed ID: 20455334
    [No Abstract]   [Full Text] [Related]  

  • 5. Evidence-based treatment of cancer-related breakthrough pain with opioids.
    Zeppetella G
    J Natl Compr Canc Netw; 2013 Mar; 11 Suppl 1():S37-43. PubMed ID: 23520185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
    Überall MA
    MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review.
    Rogríguez D; Urrutia G; Escobar Y; Moya J; Murillo M
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):228-46. PubMed ID: 26458018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
    Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
    Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the pharmacokinetic profile of transmucosal fentanyl formulations.
    Moore N; Darwish M; Amores X; Schneid H
    Curr Med Res Opin; 2012 Nov; 28(11):1781-90. PubMed ID: 23020252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Breakthrough pain and short-acting opioids].
    Beutlhauser T; Oeltjenbruns J; Schäfer M
    Anaesthesist; 2013 Jun; 62(6):431-9. PubMed ID: 23754483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl].
    Yomiya K; Kaneshima M; Kyosaka B; Warita E; Hosonuma R; Osato S
    Gan To Kagaku Ryoho; 2017 Apr; 44(4):289-293. PubMed ID: 28428506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
    Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review.
    Gordon DB
    Oncol Nurs Forum; 2006 Nov; 33(2):257-64. PubMed ID: 16518441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Breakthrough pain frequency in cancer patients and the efficiency of oral transmucosal fentanyl citrate].
    Bilen A; Ali A; Baturay F; Altan A
    Agri; 2010 Jul; 22(3):103-8. PubMed ID: 20865581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New formulations of fentanyl for acute pain management.
    Paech MJ; Bloor M; Schug SA
    Drugs Today (Barc); 2012 Feb; 48(2):119-32. PubMed ID: 22384452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough pain: progress in management.
    Lossignol DA; Dumitrescu C
    Curr Opin Oncol; 2010 Jul; 22(4):302-6. PubMed ID: 20489619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacoeconomics of breakthrough cancer pain.
    Kuo KL; Saokaew S; Stenehjem DD
    J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):167-75. PubMed ID: 23688496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
    Portenoy RK; Messina J; Xie F; Peppin J
    Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fentanyl effervescent buccal tablets: new formulation. For cancer patients with breakthrough pain: a second buccal formulation with minimal evaluation.
    Prescrire Int; 2009 Oct; 18(103):205. PubMed ID: 19882786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.